Rare cancers present one of the greatest challenges in modern oncology. Individually uncommon but collectively accounting for around one in five cancer diagnoses worldwide, they have historically attracted less research funding, fewer clinical trials and limited treatment options compared with more common malignancies. Among them, sarcomas remain particularly complex, comprising more than 100 distinct subtypes, each with unique biological characteristics and often affecting children and young adults.
For many years, treatment advances in sarcoma lagged behind those seen in breast, lung and melanoma cancers. Small patient populations made large clinical trials difficult, pharmaceutical investment was limited, and clinicians frequently relied on treatments that had changed little over decades. Today, however, that landscape is changing. Landmark international clinical trials are demonstrating that precision medicine and immunotherapy can deliver meaningful improvements for patients with rare sarcomas, while also providing the evidence needed for governments to fund these therapies and make them accessible.
Two recent studies illustrate this evolution. The CASPS trial investigating cediranib in alveolar soft-part sarcoma (ASPS) and the SU2C-SARC032 study evaluating pembrolizumab in high-risk soft tissue sarcoma represent milestones in translational cancer research. Together, they demonstrate how scientific discovery progresses from laboratory insight to international clinical collaboration, ultimately influencing healthcare policy and improving patient outcomes.
Alveolar soft-part sarcoma is one of the rarest soft tissue sarcomas, accounting for less than one percent of all soft tissue sarcomas. It predominantly affects adolescents and young adults and is characterised by slow tumour growth but an aggressive tendency to metastasise, particularly to the lungs and brain. Conventional chemotherapy has historically offered little clinical benefit, leaving patients with few evidence-based therapeutic options.
Advances in molecular biology, however, revealed that ASPS is an exceptionally vascular tumour driven by pathways involved in angiogenesis. This understanding led researchers to investigate cediranib, an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF) receptors.
Published in The Lancet Oncology in 2019, the Cediranib in Alveolar Soft-Part Sarcoma (CASPS) study was the first randomised, double-blind, placebo-controlled Phase II trial undertaken in this ultra-rare disease. Conducted across specialist sarcoma centres in the United Kingdom, Australia and Spain, the study demonstrated that high-quality randomised trials are achievable even in extremely rare cancers when international collaboration is embraced.
The study confirmed clinically meaningful antitumour activity with cediranib, with patients experiencing significantly improved disease control compared with placebo. Equally important, treatment was generally well tolerated, with adverse effects consistent with VEGF inhibition and manageable through routine clinical care.
Beyond its immediate therapeutic implications, the CASPS trial represented a landmark for rare cancer research. It demonstrated that biological understanding of a tumour could successfully guide targeted therapy development and showed that collaborative international networks could generate robust evidence in diseases where traditional large-scale clinical trials would otherwise be impossible.
While targeted therapy has transformed management for selected sarcoma subtypes, immunotherapy has emerged as another major advance in oncology. Immune checkpoint inhibitors such as pembrolizumab have revolutionised treatment across numerous cancers by restoring the immune system’s ability to recognise and eliminate malignant cells. Until recently, however, evidence supporting their use in soft tissue sarcoma remained limited.
That changed with publication of the SU2C-SARC032 study in The Lancet in 2024. This international randomised clinical trial evaluated whether adding pembrolizumab to standard pre-operative radiotherapy and surgery could improve outcomes for patients with high-risk, localised soft tissue sarcoma of the extremity.
The results were significant. Patients receiving pembrolizumab alongside standard treatment experienced substantially improved disease-free survival compared with those receiving radiotherapy and surgery alone. The addition of immunotherapy reduced the risk of recurrence or death by approximately 39 percent and increased two-year disease-free survival from 52 percent to 67 percent, representing one of the most important advances in the management of high-risk localised soft tissue sarcoma in recent years.
Importantly, these findings extended beyond academic publication. Robust clinical evidence is the cornerstone of reimbursement decisions within publicly funded healthcare systems. The strength of the SU2C-SARC032 data contributed to Australia’s Pharmaceutical Benefits Scheme (PBS) listing of pembrolizumab for eligible patients, ensuring that an effective treatment became accessible without the prohibitive financial burden that frequently accompanies novel cancer therapies.
This progression, from biological discovery and international clinical research to public reimbursement, illustrates the full translational pathway that modern oncology strives to achieve. Scientific breakthroughs only realise their true value when patients can access them in routine clinical practice.
Australia has played an important role in this journey. Despite its relatively small population, Australia continues to contribute disproportionately to international sarcoma research through collaborative clinical trials, translational science and multidisciplinary sarcoma centres. Australian investigators have participated in global research networks that enable rare cancer studies to recruit sufficient patient numbers while maintaining rigorous scientific standards.
This international approach has become essential. Rare cancers cannot be adequately studied within national borders alone. Collaboration across continents enables researchers to answer clinically important questions, validate promising therapies and accelerate regulatory approvals that ultimately benefit patients worldwide.
Nevertheless, important challenges remain. Rare cancers continue to receive disproportionately less research funding than common malignancies, despite collectively affecting millions of people globally. Recruitment into clinical trials remains difficult because eligible patients are geographically dispersed, and access to novel therapies varies considerably between healthcare systems depending on regulatory and reimbursement frameworks.
These disparities highlight the need for continued international investment in rare cancer research, harmonised regulatory pathways and policies that ensure timely patient access once clinical benefit has been demonstrated. Precision oncology is advancing rapidly, with increasing emphasis on biomarker-driven treatment selection, rational combinations of targeted therapy and immunotherapy, and adaptive clinical trial designs capable of evaluating multiple rare tumour subtypes simultaneously.
The lessons from the CASPS and SU2C-SARC032 studies extend well beyond sarcoma. They demonstrate that innovation is most effective when scientific discovery, international collaboration, clinical excellence and healthcare policy operate as parts of the same ecosystem. Each stage depends upon the other. Without biological insight there is no therapeutic target. Without clinical trials there is no evidence. Without reimbursement there is no equitable access.
For patients diagnosed with rare sarcomas, these developments represent far more than incremental scientific progress. They represent the emergence of new treatment options where few previously existed, greater confidence that rare cancers deserve the same rigorous research as common malignancies, and renewed optimism that advances in precision medicine can be translated into tangible improvements in survival and quality of life.
The future of sarcoma care will continue to depend upon collaboration across disciplines and across borders. As new targeted therapies, immunotherapies and combination approaches emerge, maintaining investment in clinical research and ensuring equitable access to innovation must remain global priorities.
Ultimately, the success of cancer research should not be measured solely by publications or discoveries. It should be measured by its ability to change clinical practice, influence health policy and improve the lives of patients. The journeys of cediranib and pembrolizumab demonstrate exactly how that transformation can occur, and why continued commitment to rare cancer research remains one of the most important investments in the future of oncology.
Author Bio
